695 related articles for article (PubMed ID: 27535102)
1. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
2. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
3. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
4. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: Prevention of late autoimmune complications by early intervention.
Abu El-Asrar AM; Al Rashed FA; AlBloushi AF; Tobaigy MF; Gikandi PW; Herbort CP; Opdenakker G
Acta Ophthalmol; 2023 Mar; 101(2):e236-e245. PubMed ID: 36128841
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
8. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
9. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation.
Keino H; Goto H; Usui M
Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):878-82. PubMed ID: 12397437
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
[TBL] [Abstract][Full Text] [Related]
11. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
Read RW; Yu F; Accorinti M; Bodaghi B; Chee SP; Fardeau C; Goto H; Holland GN; Kawashima H; Kojima E; Lehoang P; Lemaitre C; Okada AA; Pivetti-Pezzi P; Secchi A; See RF; Tabbara KF; Usui M; Rao NA
Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.
Shen E; Rathinam SR; Babu M; Kanakath A; Thundikandy R; Lee SM; Browne EN; Porco TC; Acharya NR
Am J Ophthalmol; 2016 Aug; 168():279-286. PubMed ID: 27296490
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
16. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids.
Hirooka K; Saito W; Namba K; Mizuuchi K; Iwata D; Hashimoto Y; Ishida S
PLoS One; 2017; 12(2):e0172612. PubMed ID: 28241069
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
Vukojević M; Vukojevic N; Vuković A; Rupčić B; Blažević M; Blažević A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):229-231. PubMed ID: 38651852
[TBL] [Abstract][Full Text] [Related]
18. Vogt-Koyanagi-Harada disease in children.
Abu El-Asrar AM; Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D
Eye (Lond); 2008 Sep; 22(9):1124-31. PubMed ID: 17479116
[TBL] [Abstract][Full Text] [Related]
19. EFFICACY OF COMBINED SYSTEMIC CORTICOSTEROID AND EARLY IMMUNOMODULATORY THERAPY WITHIN THREE MONTHS OF ONSET IN VOGT-KOYANAGI-HARADA DISEASE.
Park HS; Park HY; Lee CS; Lee SC; Lee JH
Retina; 2022 Dec; 42(12):2361-2367. PubMed ID: 36394890
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada disease.
O'Keefe GA; Rao NA
Surv Ophthalmol; 2017; 62(1):1-25. PubMed ID: 27241814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
